Unlocking the Potential of A-Site Ca-Doped LaCo0.2Fe0.8O3-δ: A Redox-Stable Cathode Material Enabling High Current Density in Direct CO2 Electrolysis.

Massive carbon dioxide (CO2) emission from recent human industrialization has affected the global ecosystem and raised great concern for environmental sustainability. The solid oxide electrolysis cell (SOEC) is a promising energy conversion device capable of efficiently converting CO2 into valuable chemicals using renewable energy sources. However, Sr-containing cathode materials face the challenge of Sr carbonation during CO2 electrolysis, which greatly affects the energy conversion efficiency and long-term stability. Thus, A-site Ca-doped La1-xCaxCo0.2Fe0.8O3-δ (0.2 ≤ x ≤ 0.6) oxides are developed for direct CO2 conversion to carbon monoxide (CO) in an intermediate-temperature SOEC (IT-SOEC). With a polarization resistance as low as 0.18 Ω cm2 in pure CO2 atmosphere, a remarkable current density of 2.24 A cm-2 was achieved at 1.5 V with La0.6Ca0.4Co0.2Fe0.8O3-δ (LCCF64) as the cathode in La0.8Sr0.2Ga0.83Mg0.17O3-δ (LSGM) electrolyte (300 µm) supported electrolysis cells using La0.6Sr0.4Co0.2Fe0.8O3-δ (LSCF) as the air electrode at 800 °C. Furthermore, symmetrical cells with LCCF64 as the electrodes also show promising electrolysis performance of 1.78 A cm-2 at 1.5 V at 800 °C. In addition, stable cell performance has been achieved on direct CO2 electrolysis at an applied constant current of 0.5 A cm-2 at 800 °C. The easily removable carbonate intermediate produced during direct CO2 electrolysis makes LCCF64 a promising regenerable cathode. The outstanding electrocatalytic performance of the LCCF64 cathode is ascribed to the highly active and stable metal/perovskite interfaces that resulted from the in situ exsolved Co/CoFe nanoparticles and the additional oxygen vacancies originated from the Ca2Fe2O5 phase synergistically providing active sites for CO2 adsorption and electrolysis. This study offers a novel approach to design catalysts with high performance for direct CO2 electrolysis.

N-methylformamide induces multiple organ toxicity in Fischer 344 rats.

N-Methylformamide (NMF) is a widely used chemical (CAS No.: 123-39-7) in several industries and its usage is continuously increasing. However, studies for NMF have been focused on hepatotoxicity from now. Its toxicity profile has not yet been established owing to limited toxicity data. Therefore, we evaluated systemic toxicity via NMF inhalation. We exposed 0, 30, 100, and 300 ppm NMF to Fischer 344 rats for 6 h/day, 5 days a week for 2 weeks. Clinical signs, body weights, food consumption, hematologic parameters, serum chemistry measurements, organ weights, necropsy, and histopathology were performed. Two females exposed to 300 ppm NMF died during exposure period. Decrease of food consumption and body weight in both sexes exposed to 300 ppm in females exposed to 100 ppm were noted during exposure period. Increased RBC and HGB were noted in females exposed to 300 ppm. A decrease in the levels of ALP and K and increase in the levels of TCHO and Na were observed in both sexes exposed to 300 and 100 ppm. Increased levels of ALT, AST, BUN and decreased levels of TP, ALB, Ca were observed in females exposed to 300 and 100 ppm. The relative liver weight was elevated in both sexes exposed to 300 and 100 ppm NMF. Hypertrophy in the liver and submandibular glands and nasal cavity injuries were noted in both sexes exposed to 300 and 100 ppm NMF. Tubular basophilia of the kidneys were noted in females exposed to 300 ppm NMF. We revealed that NMF affect several organs including the kidneys not only the liver and NMF-related toxicity is predominant in female rats. These results could contribute to the development of NMF toxicity profile and may help in developing strategies for the control of occupational environmental hazards related to NMF.

Thirteen-week inhalation toxicity study of 1-propanol in F344 rats.

1-Propanol is a colorless volatile liquid at room temperature and is an important industrial alcohol. Workers are potentially exposed to it through inhalation during industrial activities, including manufacturing, sampling, filling, and mixing processes, as well as during cleaning, maintenance, and repair. Consequently, further information and/or testing for inhalation-related toxicological data is required to assess occupational risk. In this study, 80 (40 male and 40 female) F344 rats were exposed to 1-propanol vapors for 13 weeks (6 h a day, 5 days per week) at target concentrations of 0, 500, 1,600, and 5200 ppm in a whole-body inhalation chamber system. Clinical signs, mean body weight changes, food consumption, hematology, blood biochemistry, necropsy, organ weight, and histopathological findings were observed. The exposure concentrations in chambers were 501.30 ± 9.54 ppm, 1605.43 ± 66.55 ppm, and 5202.19 ± 102.74 ppm for the low, middle, and high dose groups, respectively. No changes related to 1-propanol were observed, including histopathological findings, except for mean body weight changes. The significant decrease in mean body weight at a high dose was not considered to be an adverse effect. Based on these results, the no observed adverse effect concentration of 1-propanol was estimated to be 5202.19 ppm.

Four-week inhalation toxicity study of 1-propanol in F344 rats.

1-Propanol is used as a solvent for waxes, vegetable oils, resins, cellulose esters, and ethers, and is not considered harmful to humans by food and non-occupational exposures. However, workers are potentially exposed to 1-propanol by inhalation when it is used in the workplace. Thus, inhalation toxicity data are needed to assess the hazard of 1-propanol for workers safety. Five male and five female F344 rats were exposed to 1-propanol vapor for 4-weeks (6 h/day, 5 days/week) at concentrations of 0, 100, 400, and 1600 ppm in a whole-body inhalation chamber system. The actual exposure concentrations were 100.11 ± 5.10, 403.19 ± 12.31, and 1598.08 ± 139.58 ppm for the low, middle, and high dose groups, respectively. No clinical signs, significant mean body weight changes, significant changes of hematology or blood biochemistry results, or histopathological abnormalities were seen related to exposure to the test substance. Under the conditions of this study, the no-observed-adverse-effect level of 1-propanol was over 1600 ppm.

Evaluation of 1-Propanol Toxicity in B6C3F1 Mice via Repeated Inhalation over 28 and 90 Days.

We evaluated the toxicity of 1-propanol exposure following repeated inhalation over 28- and 90-day periods in male and female B6C3F1 mice to confirm the potential target organs and to determine the no-observable-adverse-effect levels (NOAELs). Five mice of each sex were exposed to 1-propanol at concentrations of 0, 100, 400, or 1600 ppm for 28 days and showed no consequent toxicity. Following this, ten mice of each sex were exposed at concentrations of 0, 500, 1600, or 5200 ppm for 90 days. We observed no effects on food consumption, body weight, organ weight, clinical signs, hematology and biochemistry parameters, or gross or histological features even at the maximum concentration. Therefore, the NOAEL of inhaled 1-propanol was defined as 5200 ppm (12.8 mg/L) for male and female mice under study conditions.

Novel Hg2+-Selective Signaling Probe Based on Resorufin Thionocarbonate and its µPAD Application.

In this study, a novel resorufin thionocarbonate-based Hg2+-selective signaling probe (RT) for microfluidic paper-based analytical device (µPAD) applications is reported. The designed probe, RT, was readily synthesized by the one-step reaction of resorufin with phenyl thionochloroformate. The RT probe displayed a prominent color change from yellow to pink and a marked turn-on fluorescence signaling behavior exclusively toward the Hg2+ ion. The signaling of RT was due to Hg2+-induced hydrolysis of the phenyl thionocarbonate moiety to form the parent resorufin dye, which restored its spectroscopic properties. In addition, RT exhibited the Hg2+-selective signaling behavior without interference by coexisting environmentally relevant metal ions. The detection limit for Hg2+ in simulated wastewater samples was estimated to be 5.8 × 10-8 M. In particular, an RT-equipped µPAD prepared using a wax printing technique enabled simple and convenient determination of Hg2+ ions in simulated wastewater samples, with a detection limit of 5.9 × 10-6 M.

Operation Protocols To Improve Durability of Protonic Ceramic Fuel Cells.

To develop reliable and durable protonic ceramic fuel cells (PCFCs), the impacts of the operation protocols of PCFCs on the cell durability are investigated through analyses of the main degradation mechanisms. We herein propose three appropriately designed control protocols, including cathode air depletion, shunt current, and fuel cell/electrolysis cycling, to fully circumvent the operating-induced degradation of PCFCs. For this purpose, anode-supported cells, comprised of a NiO-BaCe0.7Zr0.1Y0.1Yb0.1O3-δ anode, BaCe0.7Zr0.1Y0.1Yb0.1O3-δ electrolyte, and NdBa0.5Sr0.5Co1.5Fe0.5O5+δ-Nd0.1Ce0.9O2-δ composite cathode, are prepared, and their long-term performances are evaluated under a galvanostatic condition of 0.5 A·cm-2 at 650 °C. The cell voltages of the protected cells using the operation protocols to prevent performance degradation are stably maintained under the applied current density for more than 1200 h without any noticeable degradation, whereas the performance of the unprotected cell gradually decreased with time, and the decay ratio was 14.9% over 850 h. The significant performance decay of the unprotected cell is strongly associated with the cathode degradation phenomenon, which was caused by the water vapor continuously produced during the electrochemical reactions. Hence, the performance recovery of the PCFCs with the operation protocols is achieved by incrementally decreasing the cathode potential (close to a value of zero) to minimize the effect of high PH2O and PO2 during the PCFC operations.

Model selection and diagnostics for joint modeling of survival and longitudinal data with crossing hazard rate functions.

Comparison of two hazard rate functions is important for evaluating treatment effect in studies concerning times to some important events. In practice, it may happen that the two hazard rate functions cross each other at one or more unknown time points, representing temporal changes of the treatment effect. Also, besides survival data, there could be longitudinal data available regarding some time-dependent covariates. When jointly modeling the survival and longitudinal data in such cases, model selection and model diagnostics are especially important to provide reliable statistical analysis of the data, which are lacking in the literature. In this paper, we discuss several criteria for assessing model fit that have been used for model selection and apply them to the joint modeling of survival and longitudinal data for comparing two crossing hazard rate functions. We also propose hypothesis testing and graphical methods for model diagnostics of the proposed joint modeling approach. Our proposed methods are illustrated by a simulation study and by a real-data example concerning two early breast cancer treatments.

The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Major depressive disorder is a prevalent recurrent medical syndrome associated with inter-episodic dysfunction. The metabolic syndrome is comprised of several established risk factors for cardiovascular disease (i.e. abdominal obesity, dyslipidaemia, dysglycaemia and hypertension). The criterion items of the metabolic syndrome collectively represent a multi-dimensional risk factor for cardiovascular disease and type 2 diabetes mellitus. Extant evidence indicates that both major depressive disorder and the metabolic syndrome, albeit distinct, often co-occur and are possibly subserved by overlapping pathophysiology and causative mechanisms. Conventional antidepressants exert variable effects on constituent elements of the metabolic syndrome, inviting the need for careful consideration prior to treatment selection and sequencing. Initiating and maintaining antidepressant therapy should include routine surveillance for clinical and/or biochemical evidence suggestive of the metabolic syndrome.